GlobeNewswire

ObsEva Announces Third Quarter 2019 Financial Results

Share



– Reports Update on Three Women’s Health Product Candidates –

Focusing on Phase 3 Programs for Linzagolix and the Phase 2
Program for OBE022

– Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET –

                       

GENEVA, Switzerland and BOSTON, MA (November 7, 2019) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the third quarter ended September 30, 2019 and announced top line results of the IMPLANT 4 trial.

"Despite the unexpected results for IMPLANT 4, we remain optimistic and committed to the development of our innovative pipeline with potentially best in class product candidates for serving unmet medical needs of millions of women.  In particular, we are looking forward to PRIMROSE 2 study top line results, which we expect to announce this quarter” said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva.

Pipeline Update

1.       Nolasiban

IMPLANT 4 study did not meet primary endpoint: The Company has decided to discontinue the current development of nolasiban for IVF and will be exploring potential repositioning of the product.

2.       Linzagolix

· Completed Patient Randomization for Two Pivotal Phase 3 trials For Women with Uterine Fibroids (PRIMROSE 1 and PRIMROSE 2):   The studies include approximately 1,000 women in total with heavy menstrual bleeding (HMB) associated with uterine fibroids. The efficacy and safety of two oral doses of linzagolix are being studied, including 100mg once daily without hormonal add-back therapy (ABT) and 200mg once daily with ABT.

· Positive Phase 2b (EDELWEISS 1) Results Presented at the American Society of Reproductive Medicine (ASRM) Annual Meeting : ObsEva presented positive 52-week results of linzagolix for treating endometriosis-associated pain. 
· Phase 3 trials EDELWEISS 2 (U.S.) and EDELWEISS 3 (U.S. and Europe) Currently Enrolling Patients :  Each trial will enroll approximately 450 women with endometriosis-associated pain, and will include two oral doses of linzagolix, 75mg once daily without low-dose ABT and 200mg once daily with ABT. 


                                                                                                                                        
3.       OBE022 To Delay Preterm Birth


· Data Monitoring Committee Recommended Continuation of Phase 2 Study in Europe (PROLONG): In July 2019, the independent data monitoring committee (IDMC) recommended continuing the ongoing PROLONG trial with no modifications based upon the first 30 patients enrolled in Part B.  Part B is the multicenter, randomized, double-blind, placebo-controlled portion of the trial that will enroll up to 120 patients with preterm labor at a gestational age of between 24 and 34 weeks.


· 

Anticipated Near-Term Milestones

ObsEva expects to achieve the following clinical and regulatory milestones in 2019 - 2020:

Fourth quarter 2019

  • Linzagolix: Report six-month primary endpoint data from the PRIMROSE 2 Phase 3 trial (U.S. and Europe) to treat HMB due to uterine fibroids.
     
  • OBE022: Receive interim update in 60 patients dosed in Part B of the PROLONG Phase 2a trial in acute pre-term labor and decide next steps in development.

Second Quarter 2020

·Linzagolix:  Report six-month primary endpoint data from the Phase 3 PRIMROSE 1 trial (U.S.) of linzagolix for the treatment of HMB due to uterine fibroids.

Second Half 2020

  • Linzagolix:
    • Read-out 12 month data for PRIMROSE 1 and PRIMROSE 2
    • Conduct pre-submission meeting with the European Medicines Agency and the U.S. Food and Drug Administration for uterine fibroid indication.
       
  • OBEO22: Report PROLONG study final results

Third Quarter 2019 Financial Results

Net loss for the third quarter of 2019 was $27.6 million, or $0.63 per share, compared with a net loss of $18.6 million, or $0.42 per share, for the third quarter of 2018.  Research and development expenses were $21.9 million and general and administrative expenses were $4.9 million for the third quarter of 2019, compared with $15.9 million and $3.1 million, respectively, for the third quarter of 2018.  The net loss for the third quarter of 2019 included non-cash expenses of $3.0 million for stock-based compensation, compared with $2.0 million in the prior-year period.

As of September 30, 2019, the Company had cash and cash equivalents of $91.0 million, compared with $138.6 million as of December 31, 2018.

The full Q3 2019 financial report shall be available from November 11, 2019, in the financial reports section of the Company’s website.

To access the financial reports section of the Company’s website, please click [here].
To access the Q3 2019 financial report directly, please click [here].

Conference Call Today

ObsEva will host a conference call and audio webcast today beginning at 8:00 a.m. Eastern Time/2:00 p.m. Central European Time to provide a business update and discuss the third quarter results.  Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers and referring to conference ID 9273485.  A live or archived webcast of the conference call can be accessed under the “Investors” section of ObsEva’s website www.ObsEva.com.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates, the timing of enrollment in and data from clinical trials and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2018, the Risk Factors filed as Exhibit 99.1 to ObsEva’s Form 6-K filed on August 7, 2019, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
cla@dynamicsgroup.ch
+41 22 308 6220 Office
+41 79 476 26 87 Mobile

Media Contact U.S.:
Marion Janic
RooneyPartners LLC
mjanic@rooneyco.com
+1 212 223 4017 Office
+1 646 537 5649 Mobile

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile

Consolidated Statements of Comprehensive Loss

     Three-month period
ended September 30,
    Nine-Month Period
Ended September 30,
 
(in USD ’000, except share and per share data) - unaudited   2019     2018     2019     2018  
Operating income other than revenue     5       2       11       10  
OPERATING EXPENSES                                
Research and development expenses     (21,935 )     (15,909 )     (70,513 )     (46,945 )
General and administrative expenses     (4,865 )     (3,137 )     (16,306 )     (10,287 )
Total operating expenses     (26,800 )     (19,045 )     (86,819 )     (57,231 )
OPERATING LOSS     (26,795 )     (19,043 )     (86,808 )     (57,221 )
Finance income     219       430       425       616  
Finance expense     (1,021 )           (1,608 )      
NET LOSS BEFORE TAX     (27,597 )     (18,613 )     (87,991 )     (56,605 )
Income tax (expense)     (10 )     23       (51 )     23  
NET LOSS FOR THE PERIOD     (27,607 )     (18,590 )     (88,042 )     (56,582 )
Net loss per share                                
Basic     (0.63 )     (0.42 )     (2.01 )     (1.45 )
Diluted     (0.63 )     (0.42 )     (2.01 )     (1.45 )
Weighted Average Number of Shares Outstanding     43,739,938       43,196,686       43,693,245       39,092,256  

Consolidated Balance Sheets

(in USD ’000) - unaudited   September 30,
2019
    December 31,
2018
 
ASSETS                
Current assets                
Cash and cash equivalents     91,017       138,640  
Other receivables     776       885  
Prepaid expenses     5,964       5,715  
Total current assets     97,757       145,240  
Non-current assets                
Right-of-use assets     2,202        
Furniture, fixtures and equipment     261       319  
Intangible assets     26,608       21,608  
Other long-term assets     270       273  
Total non-current assets     29,341       22,200  
Total assets     127,098       167,440  
LIABILITIES AND SHAREHOLDERS’ EQUITY                
Current liabilities                
Current tax liability     46        
Other payables and current liabilities     6,515       2,766  
Accrued expenses     19,595       14,163  
Current lease liabilities     598        
Total current liabilities     26,754       16,929  
Non-current liabilities                
Non-current lease liabilities     1,665        
Non-current borrowings     24,830        
Post-employment obligations     3,608       3,547  
Other long-term liabilities     414       48  
Total non-current liabilities     30,517       3,595  
Shareholders’ equity                
Share capital     3,448       3,420  
Share premium     318,226       314,565  
Reserves     20,122       12,858  
Accumulated losses     (271,969 )     (183,927 )
Total shareholders’ equity     69,827       146,916  
Total liabilities and shareholders’ equity     127,098       167,440  

###

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Ernst Jansen new COO of Kempen Capital Management3.6.2020 08:30:00 CESTPress release

Amsterdam/’s-Hertogenbosch, the Netherlands, 3 June 2020 Ernst Jansen has been appointed Chief Operating Officer (COO) at Kempen Capital Management (Kempen) with immediate effect. The successor to Erik Luttenberg, Jansen will take on this role alongside his current position of COO of Van Lanschot Private Banking. The new position also sees him appointed to Kempen’s Management Board. Constant Korthout, Van Lanschot Kempen’s Chief Financial Officer and Chief Risk Officer (CFO/CRO), explained: “We’re very pleased that Ernst has proved willing to take on these new responsibilities alongside his current position. This appointment reflects our strategy towards a fully integrated wealth management model by 2023, allowing us to enhance our efficiency and productivity, and act as a single group. Our thanks go to Erik for his many years of service to our organisation, and we wish Ernst lots of success in his new role.” Media Relations: +31 20 354 45 85; mediarelations@vanlanschotkempen.com Inves

Rovio Entertainment has acquired Darkfire Games - Copenhagen based mobile games studio3.6.2020 08:30:00 CESTPress release

Rovio Entertainment Corporation Press Release Rovio Entertainment has acquired Darkfire Games - Copenhagen based mobile games studio June 3, 2020 - Espoo - Rovio Entertainment Corp. has acquired a free-to-play (F2P) mobile games studio Darkfire Games (formerly Wargaming Denmark), focused on Role Playing Games (RPG). Rovio acquired all of the outstanding shares of Darkfire Games for an undisclosed sum on June 3, 2020, and the wholly-owned Rovio subsidiary will become Rovio Copenhagen. Rovio Copenhagen will continue to operate as an independent studio focusing on mobile RPGs. At present, the studio comprises 20 gaming industry veterans with vast expertise in making RPGs. As part of the acquisition, Rovio takes on the studio’s currently soft-launched mobile RPG, Darkfire Heroes. The game’s development will continue in Copenhagen, with Rovio providing synergies and support for the studio in central functions and areas such as user acquisition, technology, analytics and live operations. “We

HOYLU AB: HOYLU FÅR NY ORDER FRÅN LÄKEMEDELSFÖRETAG3.6.2020 08:30:00 CESTPressemelding

Stockholm, Sverige, 3 juni 2020 – Hoylu, ledande inom visuella samarbetslösningar för distribuerade team, meddelade idag att man fått enny order från Foundation Medicine, en befintlig kund hos Hoylu inom läkemedelsindustrin. Ordervärdet uppgår till 380 000 kronor i mjukvaruintäkter. Hoylus mjukvara och lösningar erbjuder nya och spännande sätt att kommunicera och samarbeta smartare, snabbare och mer effektivt. Hoylu's Connected WorkspacesTM hjälper företagskunder att hantera sina aktiviteter, visualisera arbete och motivera människor att göra sitt bästa genom att undvika missförstånd och säkra framgång. För mer information kontakta: Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: sr@hoylu.com Karl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: kw@hoylu.com Hoylu AB Om Hoylu Hoylu s uppdrag är att göra distansarbete och informationsutbyte lätt. Genom våra anpassningsbara Connected Workspaces™ levererar vi programvarulösningar för företag, organisationer och individer i praktiskt tag

Active Biotech tillhandahåller statusuppdatering i projekten3.6.2020 08:30:00 CESTPressemelding

Lund, 3 juni 2020 - Active Biotech (Nasdaq Stockholm: ACTI) tillhandahåller idag en statusuppdatering i projekten i och med den nya inriktningen som kommunicerades i början av februari. Denna förkortade uppdatering tillhandahålls som ersättning för den kapitalmarknadsdag som tidigare planerades till den 19 maj, och som vi istället avser att genomföra under det fjärde kvartalet i år med förbehåll för status avseende Covid-19. Trots Covid-19-pandemin har de flesta aktiviteterna i våra projekt genomförts planenligt och hittills har inga projekttidslinjer påverkats väsentligt. Fas 1b/2-studien med naptumomab i kombination med checkpoint-hämmaren durvalumab hos patienter med avancerad solida tumörer syftar till att fastställa maximalt tolererad dos av kombinationen innan man går vidare i en utvidgad kohort-studie i USA. Studien fortskrider enligt plan och vi ser fram emot att meddela resultaten från doseskaleringsfasen i denna studie senare i år. I tasquinimod-projektet, som är inriktat på

HOYLU AB: HOYLU RECEIVES NEW ORDER FROM PHARMA COMPANY3.6.2020 08:30:00 CESTPress release

Stockholm, Sweden, June 3, 2020 – Hoylu, a leader in visual collaboration solutions for distributed teams, announced today that it has received a new order from Foundation Medicine, an existing customer of Hoylu in the pharma sector. The deal value is SEK 380,000 in software revenue. Hoylu’s software and solutions offer new and exciting ways to communicate and collaborate smarter, faster and more efficiently. Hoylu's Connected Workspaces™ help enterprise clients manage activities, visualize work and motivate people to perform their best by avoiding miscommunication and secure success. For more information, please contact: Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: sr@hoylu.com Karl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: kw@hoylu.com Hoylu AB About Hoylu Hoylu’s mission is to make remote work and information sharing easy. Through our customizable Connected Workspaces™ we deliver software solutions for companies, organizations and individuals across virtually all industr

Active Biotech provides status update in the portfolio projects3.6.2020 08:30:00 CESTPress release

Lund, June 3, 2020 - Active Biotech (Nasdaq Stockholm: ACTI) today provides a status update in the projects following the new direction communicated in early February. This abbreviated update is provided as a midterm replacement of the Capital Markets Day previously announced for May 19, which we now instead are planning to host during Q4 this year subject to the status of Covid-19. Despite the Covid-19 pandemic, most activities in our projects have proceeded according to plan and, so far, no project timelines have been significantly affected. The Phase 1b/2 study with naptumomab in combination with the checkpoint inhibitor durvalumab in patients with advanced solid tumors aims to establish the maximum tolerated dose of the combination before advancing to a larger cohort expansion phase in the United States. The study is enrolling according to plan and we look forward to reviewing results from the dose escalation phase of this trial later this year. In the tasquinimod project, which is